Navigation Links
PTC Therapeutics Initiates Phase 2 Clinical Trial of PTC299 in Patients with Neurofibromatosis Type 2
Date:7/27/2009

PTC 299 is a novel, orally administered small-molecule compound that inhibits the production of the protein vascular endothelial growth factor (VEGF) in tumors. PTC discovered PTC299 through PTC's proprietary GEMS (Gene Expression Modulation by Small-Molecules) technology by targeting the post-transcriptional processes that regulate VEGF formation. Overexpression of VEGF plays a key role in the growth of many types of tumors. PTC299 selectively blocks the tumor-related production of VEGF through a mechanism that is distinct from that of other VEGF inhibitors, while sparing the physiological VEGF expression necessary to maintain the growth and function of normal blood vessels. Clinical trials are currently ongoing in metastatic breast cancer, Kaposi sarcoma, and other solid tumors. For more information regarding PTC299 clinical trials, visit www.clinicaltrials.gov and search "PTC299".

About PTC Therapeutics

PTC is a biopharmaceutical company focused on the discovery, development and commercialization of orally administered, proprietary, small-molecule drugs that target post-transcriptional control processes. Post-transcriptional control processes regulate the rate and timing of protein production and are of central importance to proper cellular function. PTC's internally discovered pipeline addresses multiple therapeutic areas, including genetic disorders, oncology, and infectious diseases. PTC has extensive knowledge of post-transcriptional control processes and has developed proprietary technologies that it applies in its drug discovery activities have been the basis for collaborations with leading biopharmaceutical companies such as Celgene, Genzyme, Gilead, Pfizer, and Schering-Plough. For more information, visit the company's Web site at www.ptcbio.com.

<
'/>"/>

SOURCE PTC Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Orexigen(R) Therapeutics Announces Full Exercise of Overallotment Option by Underwriters
2. United Therapeutics Corporation to Announce Second Quarter 2009 Financial Results Before Market Open on Friday, July 31, 2009
3. Cell Therapeutics, Inc. Announces Exercise of Overallotment
4. Northwest Biotherapeutics Announces Plans to De-list From AIM and Consolidate its Stock Market Listing in U.S.
5. Cell Therapeutics, Inc. Announces Pricing of Public Offering of Common Stock and Warrants
6. Sirnaomics Receives SBIR Grant from NIH/NCI for Its Multi-Targeted Lung Cancer siRNA Therapeutics
7. Tobira Therapeutics Inc. Announces Phase I Data Demonstrating Pharmacokinetic Properties of TAK-652 for the Treatment of HIV
8. Hygeia Therapeutics Signs an Exclusive License with Yale University for Potent, Safe Topical Anti-Androgens
9. Nile Therapeutics, Inc. Completes $3.4 Million Private Placement
10. Oxygen Biotherapeutics, Inc. Announces Closing of Private Placement Financing Agreement
11. Cornerstone Therapeutics Inc. Announces Record Date and Meeting Date for Special Meeting of Stockholders for Vote with Respect to Charter Amendments
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/27/2015)...  Tikcro Technologies Ltd. (OTCQB: TIKRF) today reported results ... Aviv Boim , CEO of Tikcro ... generate functional specific antibodies, targeting identified cancer immune checkpoints. ... by the development progress. We are excited to invest ... immune checkpoints gain clinical acceptance for cancer treatment."Net loss ...
(Date:5/27/2015)... BETHESDA, Md. , May 27, 2015  Northwest ... biotechnology company developing DCVax® personalized immune therapies for cancer, ... Chief Technical Officer of the Company, will be making ... Annual Meeting in Chicago on ... CDT, at the Industry Expert Theater in McCormick Place. ...
(Date:5/27/2015)... 2015  RXi Pharmaceuticals Corporation (NASDAQ: RXII ... developing innovative therapies primarily in the areas of ... status of the Company,s Series A and Series ... http://photos.prnewswire.com/prnh/20130917/NE80755LOGO At March ... of Series A Preferred Stock and Series A-1 ...
(Date:5/26/2015)... Regenestem Network has announced the grand opening ... Argentina. The clinic will be lead by Silvina Pastrana, ... a multidisciplinary team of medical professionals who specialize in ... office. , The new Regenestem Network members plan ... in cellular therapies, and establish Regenestem protocols to isolate ...
Breaking Biology Technology:Tikcro Technologies Reports First Quarter 2015 Results 2Tikcro Technologies Reports First Quarter 2015 Results 3NW Bio To Present Overview Of DCVax-Direct Phase I Trial In Chicago This Weekend 2NW Bio To Present Overview Of DCVax-Direct Phase I Trial In Chicago This Weekend 3RXi Pharmaceuticals Provides an Update on Series A and Series A-1 Preferred Stock 2RXi Pharmaceuticals Provides an Update on Series A and Series A-1 Preferred Stock 3Regenestem Network and Silvina Pastrana, M.D. Announce the Opening of a New Stem Cell Clinic in Buenos Aires 2Regenestem Network and Silvina Pastrana, M.D. Announce the Opening of a New Stem Cell Clinic in Buenos Aires 3
... Newly proposed Medicare rules designed to promote ... closely mirror quality reporting programs already well established ... MedeAnalytics analysis has found. (Logo: ... analysis is included in MedeAnalytics, white paper, "Accountable ...
... 4, 2011 Omeros Corporation (NASDAQ: OMER ... commercializing products focused on inflammation, bleeding and disorders of ... Demopulos, M.D., chairman and chief executive officer, is scheduled ... taking place in New York City this week.  The ...
... Techne Corporation (NASDAQ: TECH ) ... its R&D Systems subsidiary has acquired the assets ... manufacturer of innovative ubiquitin-related research products.  These products ... accelerate basic research and drug discovery efforts.  R&D ...
Cached Biology Technology:ACO Proposed Rule: Nine out of Ten Quality Measures Mirror Other Quality Reporting Programs 2Techne Corporation Announces Acquisition 2Techne Corporation Announces Acquisition 3Techne Corporation Announces Acquisition 4
(Date:5/11/2015)... -- Curemark LLC, a privately held drug research and ... III double blind, randomized, placebo-controlled clinical trial to examine ... children ages 3-8 with Autism. Previously, Curemark announced the ... clinical trial for CM-AT in children ages 3-8 with ... chymotrypsin. This new trial will help determine whether all ...
(Date:5/8/2015)... -- Synaptics Inc. (NASDAQ: SYNA ), the leading developer ... executive management team will present at the following investor events: ... Conference Date: May 18, 2015 Time: 10:40am ET ... Cowen and Company Technology, Media & Telecom ... New York Palace Hotel, New York, NY ...
(Date:5/6/2015)... AVIV, Israel , May 6, 2015 ... world,s most established helmet producer, announced today that they ... Smart Helmet, the world,s first bio-sensing cycling helmet and ... be released in two new colors in order to ... for the product. In addition, LifeBEAM and Lazer announced ...
Breaking Biology News(10 mins):Curemark, LLC, Launches New Phase III Trial in Expanded Population of Children with Autism 2Synaptics to Present at Upcoming Investor Conferences 2LifeBEAM and Lazer Announce Expanded Partnership in Bio-Sensing Sports Gear 2LifeBEAM and Lazer Announce Expanded Partnership in Bio-Sensing Sports Gear 3
... Girls are hitting puberty earlier and earlier. One recent study ... some breast development by age 7. This news has upset ... cases for girls to develop faster, according to the authors ... a journal of the Association for Psychological Science. ...
... Here,s good news for anyone trying to lose weight or ... a weight loss drug that may revolutionize how we treat ... the September 2010 print issue of The FASEB Journal ... responsible for regulating body fat and bone mass. Then they ...
... that anchors itself to the sea bed, offers new clues ... Sheet a region that is thought to be vulnerable ... the Census of Antarctic Marine Life (CAML), scientists from British ... and deep sea regions around the continent and from further ...
Cached Biology News:Girls' early puberty linked to unstable environment via insecure attachment in infancy 2Scientists discover new protein that gets to the roots of obesity and osteoporosis 2Marine animals suggest evidence for a trans-Antarctic seaway 2
Mouse monoclonal antibody raised against a partial recombinant AAAS. NCBI Entrez Gene ID = AAAS...
Rabbit polyclonal to MCP2 ( Abpromise for all tested applications). entrezGeneID: 6355 SwissProtID: P49873...
... A sensitive and high speed homogeneous ... phosphatase activity and for screening of inhibitors ... kit is based on a fluorescence superquenching ... radioactive label. The universal platform provides flexibility ...
... PowerPac 3000 power supply, 220-240 V, is ... liquid-phase isoelectric focusing (IEF). The system includes ... (60 ml) focusing chambers, chassis, harvesting apparatus, ... supply, 10 ml Bio-Lyte ampholytes (pH 3-10), ...
Biology Products: